What question did this study set out to answer?

The aim is to explore the effectiveness of heterobifunctional protein degraders targeting ALK2.

May 6, 2026Journal of Medicinal Chemistry0 citationsOpen Access

Targeting Activin Receptor-like Kinase 2 Using Heterobifunctional Protein Degraders

DWDaniel T. WebbCharles River Laboratories (Netherlands)KJKatherine L. JonesCharles River Laboratories (Netherlands)NMNatsuko MacabuagCharles River Laboratories (Netherlands)

Key Points

The aim is to explore the effectiveness of heterobifunctional protein degraders targeting ALK2.
Development of compounds with improved degradation potency for ALK2.
Evaluation of the utility of these compounds in studying ALK2's role in disease.
Identified compounds enhance the degradation of ALK2.
Demonstrated potential applications in drug discovery for human diseases.

Abstract

), a compound with improved ALK2 degradation potency. The compounds described have utility for studying the role of ALK2 in human disease and possess translational potential in drug discovery.

AI에게 질문

Bookmark

View Full Paper